Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy (RGX-314 SRLTFU)

[M23-422] A Long-term Follow-Up Study to Evaluate the Safety and Efficacy of RGX-314 Following Subretinal Administration in Participants With Neovascular Age-related Macular Degeneration and Fellow Eye Treatment Substudy

Status

Recruiting

Phases

Phase 2

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT2073250145

Enrollment

Registered

2026-03-23

Start date

2026-05-22

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neovascular age-related macular degeneration

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Able and willing to provide written consent 2. Previously enrolled in a clinical study of RGX-314 and received a single subretinal administration of RGX-314

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
Incidence of ocular adverse events and any serious adverse events in the study eye	—

Countries

Canada, France, Germany, Hungary, Israel, Italy, Japan, Puerto Rico, Spain, United Kingdom, United States

Contacts

Public ContactContact for Patients and HCP

AbbVie GK

AbbVie_JPN_info_clingov@abbvie.com+81-120-587-874

Outcome results